Diversified Trust Co Has $770,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Diversified Trust Co increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.7% during the 4th quarter, HoldingsChannel reports. The fund owned 81,758 shares of the biopharmaceutical company’s stock after purchasing an additional 7,257 shares during the quarter. Diversified Trust Co’s holdings in Amicus Therapeutics were worth $770,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in FOLD. Wellington Management Group LLP lifted its position in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares during the period. Millennium Management LLC lifted its holdings in Amicus Therapeutics by 1,758.9% in the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after buying an additional 1,792,277 shares during the period. William Blair Investment Management LLC boosted its stake in Amicus Therapeutics by 12.8% in the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after acquiring an additional 1,477,084 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $13,530,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Amicus Therapeutics by 141.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after acquiring an additional 1,192,489 shares during the last quarter.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $9.46 on Friday. The firm has a market cap of $2.83 billion, a P/E ratio of -27.82 and a beta of 0.62. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.08. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The firm’s 50 day moving average price is $9.95 and its two-hundred day moving average price is $10.55.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on FOLD shares. JPMorgan Chase & Co. lifted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Bank of America boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Finally, Cantor Fitzgerald increased their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Insider Buying and Selling

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 22,901 shares of company stock valued at $259,863. Company insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.